In-Use Stability of the Rituximab Biosimilar CT-P10 (Truxima®) Following Preparation for Intravenous Infusion and Storage
Tóm tắt
CT-P10 is the first biosimilar of the anti-CD20 monoclonal antibody, rituximab. CT-P10 is currently available in over 51 countries worldwide, where it is approved in the same indications as its reference product rituximab. In-use stability studies are conducted for biologics to determine how conditions (e.g., temperature, light, humidity, length of time stored) affect drug quality following dilution and storage in infusion bags. We evaluated the in-use stability of CT-P10 for intravenous infusion stored diluted in infusion bags over longer periods than currently recommended by manufacturer guidelines. CT-P10, within the final month of its 36-month shelf life, was diluted to 1.0 or 4.0 mg/mL and stored at 2–8 °C in polyethylene or polyvinylchloride infusion bags for 2, 4, and 6 weeks. CT-P10 infusion bags were incubated at room temperature for 24 h before analysis. Analyses included detection of sub-visible particles, formation of impurities and determination of charge variants, and heavy- and light-chain content. Cell-based CD20 binding affinity and complement-dependent cytotoxicity were also assessed. Diluted CT-P10 solutions remained clear, colorless, and free of visible particles irrespective of type of infusion bag, target concentration, or timepoint. Protein concentrations, sub-visible particles, pH, osmolality, and molecular weight and charge variants were stable across all timepoints and variables. The binding affinity and potency of CT-P10 remained unchanged, indicating that the efficacy of the antibody was maintained following in-use preparation. We demonstrated that CT-P10 was stable after refrigerated storage for up to 6 weeks followed by incubation at room temperature.
Tài liệu tham khảo
Deeks ED. CT-P10 (Truxima): a rituximab biosimilar. BioDrugs. 2017;31(3):275–8.
Storz U. Rituximab: how approval history is reflected by a corresponding patent filing strategy. MAbs. 2014;6(4):820–37.
World Health Organisation. WHO model list of essential medicines. 20th list. 2017. http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1. Accessed 28 Aug 2018.
European Medicines Agency. Truxima summary of product characteristics. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004112/WC500222694.pdf. Accessed 6 Aug 2018.
European Medicines Agency. MabThera summary of product characteristics. 2003. https://ec.europa.eu/health/documents/community-register/2005/2005111510665/anx_10665_en.pdf. Accessed 28 Aug 2018.
CELLTRION, Inc. Truxima™ 100mg package leaflet. 2017. http://www.celltrion.com/resources/pdf/CT-P10%20100mg_Leaflet(EN)_final(432x498)(CLT).pdf. Accessed 6 Aug 2018.
CELLTRION, Inc. Truxima™ 500mg package leaflet. 2017. http://www.celltrion.com/resources/pdf/CT-P10%20500mg_Leaflet(UK_IE)_final(432x498)(CLT).pdf. Accessed 6 Aug 2018.
European Medicines Agency. Truxima assessment report. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/004112/WC500222695.pdf. Accessed 6 Aug 2018.
International Conference on Harmonisation Guideline. Stability testing of new drug substances and products Q1A(R2). 2003. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf. Accessed 6 Aug 2018.
International Conference on Harmonisation Guideline. Stability testing of biotechnological/biological products Q5C. 1995. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5C/Step4/Q5C_Guideline.pdf. Accessed 6 Aug 2018.
Sreedhara A, Glover ZK, Piros N, Xiao N, Patel A, Kabakoff B. Stability of IgG1 monoclonal antibodies in intravenous infusion bags under clinical in-use conditions. J Pharm Sci. 2012;101(1):21–30.
Mazzeo A, Carpenter P. Stability studies for biologics. In: Huynh-Ba K, editor. Handbook of stability testing in pharmaceutical development. New York: Springer; 2009. p. 353.
Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98(4):1201–5.
Ratanji KD, Derrick JP, Dearman RJ, Kimber I. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 2014;11(2):99–109.
Vlasak J, Ionescu R. Fragmentation of monoclonal antibodies. MAbs. 2011;3(3):253–63.
Zhang Y, Vermeulen LC, Kolesar JM. Stability of stock and diluted rituximab. Am J Health Syst Pharm. 2013;70(5):436–8.
Paul M, Vieillard V, Jaccoulet E, Astier A. Long-term stability of diluted solutions of the monoclonal antibody rituximab. Int J Pharm. 2012;436(1–2):282–90.
Vieillard V, Paul M, Ibrahim T, Astier A. Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bags. Ann Pharm Fr. 2017;75(6):420–35.
Lamanna WC, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, et al. The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion. J Oncol Pharm Pract. Epub 2017 Jan 1. https://doi.org/10.1177/1078155217731506.